Progressive and incurable, Alzheimer’s disease affects an estimated 6.7 million U.S. adults at least 65 years old, according ...

Sue Bell was one of the first patients to receive the Alzheimer's drug lecanemab in 2020 as part of the clinical trial. It didn't stop the disease.

Two widely touted Alzheimer’s drugs have been shown to enable patients to remain in their homes for longer periods of time.

The available drugs for Alzheimer’s could only temporarily ease some symptoms—not change anything about the underlying ...

With early diagnosis of Alzheimer's disease comes the possibility of treatment to not only help manage symptoms but also slow ...

In “Doctored,” Charles Piller uncovers evidence that many important Alzheimer’s studies are based on faulty data.

A new study found that some medications could have the unintended benefit of reducing dementia risk, while others could ...

Alzheimer's disease, a type of dementia that profoundly alters a person’s memory and cognitive function, affects an estimated ...

Biogen and Eisai have spent much of Leqembi’s launch convincing physicians and patients that it’s safe to treat Alzheimer’s ...

Lecanemab has given us more years together. That’s not ‘minute’ nor ‘minimal’ to me,” writes one reader in STAT’s letters to ...

Imagine you have just been diagnosed with mild cognitive decline due to Alzheimer’s disease ... daily activities without ...

lecanemab (Leqembi) and donanemab (Kisunla). Both FDA-approved medications are designed to remove amyloid beta plaques from the brains of people with early-stage Alzheimer's disease, potentially ...